Why Arcturus Therapeutics Holdings Inc.’s (ARCT) Stock Is Up 5.06%
As of Monday, July 27, Arcturus Therapeutics Holdings Inc.’s ARCT share price has surged by 5.06%, which has investors questioning if this is right time to sell.Michael Rose
Stock Evaluator: Arcturus Therapeutics Holdings Inc. (ARCT)
Arcturus Therapeutics Holdings Inc. ARCT
$5.76
-0.16
-2.70%
July 31, 2026 4:00:00 PM
EST
Volume: 266,640
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency. In addition, it develops KOSTAIVE, a self-amplifying RNA vaccine for COVID-19; ARCT-2138 (LUNAR-FLU), which is in Phase1 clinical trial for the treatment of seasonal influenza; and ARCT-2304 (LUNAR-H5N1) that is in Phase1 clinical trial for the treatment of Pandemic Influenza. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
Commentary & Analysis
Why Arcturus Therapeutics Holdings Inc.’s (ARCT) Stock Is Down 6.03%
As of Thursday, July 16, Arcturus Therapeutics Holdings Inc.’s ARCT share price has dipped by 6.03%, which has investors questioning if this is right time to buy.Michael Rose
Why Arcturus Therapeutics Holdings Inc.’s (ARCT) Stock Is Down 6.64%
As of Wednesday, July 08, Arcturus Therapeutics Holdings Inc.’s ARCT share price has dipped by 6.64%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Arcturus Therapeutics Holdings Inc.'s (ARCT) Stock Is Up 15.67%
As of Thursday, July 02, Arcturus Therapeutics Holdings Inc.’s ARCT share price has surged by 15.67%, which has investors questioning if this is right time to sell.
Jenna Brashear
Why Arcturus Therapeutics Holdings Inc.’s (ARCT) Stock Is Up 5.11%
As of Wednesday, June 17, Arcturus Therapeutics Holdings Inc.’s ARCT share price has surged by 5.11%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | ARCT | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $163.7 | $252.6 | 26% |
|
| Shares Out (Mil) | 28.4 | 52.3 | 36% |
|
| Institutional Ownership | 90.8% | 92.1% | 59% |
|
| Float (Mil) | 26.2 | 40.2 | 33% |
|
| Beta | 2.43 | 0.95 | 96% |
|
| Avg Daily Volume (000s) | 414 | 455 | 56% |
|
| Price Change (52-week) |
(54.5%) | 52.9% | 14% |
|
| Growth | ARCT | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 53.9% | 13.6% | 96% |
|
| Net Income (5yr) | 1.8% | (9.9%) | 42% |
|
| EPS (5yr) | 7.5% | 16.0% | 42 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (16.2%) | (15.6%) | 45% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 11 | 11 | 11 | |
| Current EPS | ($1.026) | ($3.858) | ($4.024) | |
| Month Ago EPS | ($1.031) | ($3.867) | ($3.992) | |
| # Rev Up | 0 | 1 | 0 | |
| # Rev Down | 1 | 0 | 1 | |
| Three Months Ago EPS | ($1.032) | ($4.025) | ($4.208) | |
| Year/Year Chg | 8.1% | 60.6% | 46.0% | |
| Financials | ARCT | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $55 | $38 | 21% |
|
| Net Income (TTM) (Mil) | ($79) | ($43) | 12% |
|
| EPS (TTM) | ($2.839) | ($1.600) | 12% |
|
| Operating Cash Flow (TTM) (Mil) | ($59) | ($31) | 8% |
|
| Net Cash Flow (TTM) (Mil) | ($60) | $5 | 18% |
|
| Long-Term Debt (Q1) (Mil) | $20 | $5 | 33% |
|
| Enterprise Value (Q1) (Mil) | $75 | $180 | 19% |
|
| Valuation | ARCT | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.86 | 2.56 | 18% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | ARCT | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (80.7%) | 63.8% | 2% |
|
| Net Margin | (143.8%) | (67.3%) | 6% |
|
| ROA | (27.3%) | (49.8%) | 18% |
|
| ROE | (37.0%) | (55.5%) | 18% |
|
| Liabilities to Assets | 22.0% | 30.3% | 14% |
|
| F-Score | 3 | 3 | 19% |
|
Arcturus Therapeutics Holdings Inc. did not pass any screens on 7/31/2026.
